Eloxx Pharmaceuticals says FDA cleared IND for Exaluren in nonsense-mutation polycystic kidney disease, Phase 2 topline expected H1 2029

Eloxx Pharmaceuticals said the FDA cleared its investigational new drug application for Exaluren in nonsense-mutation polycystic kidney disease, with Phase 2 topline data expected in the first half of 2029.

Detected & updated continuously · Source: Nebula